Related Experiment Videos
Inflammatory bio-markers and cardiovascular risk prediction
1Center for Cardiovascular Disease Prevention and the Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, 900 Commonwealth Avenue East, Boston, MA 02215, USA.
Insights
Inflammation, particularly C-reactive protein (CRP), is key in atherosclerosis. Elevated CRP predicts cardiovascular events in various populations, suggesting its direct role and aiding risk assessment.
Area of Science:
- Cardiovascular Science
- Inflammation Research
- Atherosclerosis Pathogenesis
Background:
- Inflammatory processes are central to atherosclerosis development and complications.
- Plasma inflammatory markers, including C-reactive protein (CRP), correlate with cardiovascular risk.
- Emerging evidence suggests CRP's direct role in atherogenesis, potentially produced within arterial plaques.
Purpose of the Study:
- To review the role of inflammatory markers, especially CRP, in cardiovascular risk.
- To assess CRP's predictive value for cardiovascular events in diverse populations.
- To evaluate the potential of combining inflammatory markers with lipid testing for risk stratification.
Main Methods:
- Review of existing clinical studies and research on inflammatory markers and cardiovascular disease.
- Analysis of associations between plasma CRP levels and cardiovascular risk.
- Examination of CRP's potential direct involvement in atherogenesis.
Main Results:
- Elevated CRP levels are associated with increased risk of myocardial infarction, stroke, peripheral vascular disease, and cardiovascular death.
- CRP is a strong predictor of cardiovascular risk in acute coronary syndromes and apparently healthy individuals.
- Arterial plaque may produce CRP independently of hepatic synthesis.
Conclusions:
- Inflammatory markers, particularly CRP, are significant predictors of cardiovascular risk.
- Integrating CRP measurement with lipid profiles may enhance cardiovascular risk stratification.
- Lifestyle interventions (exercise, weight loss, smoking cessation) are recommended for elevated CRP.
- Further research is needed to confirm statin efficacy in individuals with high CRP levels.
Abstract:
Inflammatory processes are now recognized to play a central role in the pathogenesis of atherosclerosis and its complications. Plasma levels of several markers of inflammation have been found to be associated with future cardiovascular risk in a variety of clinical settings. These markers include cell adhesion molecules, cytokines, pro-atherogenic enzymes and C-reactive protein (CRP). Initially thought of as an inactive downstream marker of the inflammatory cascade, emerging evidence suggests that CRP may be directly involved in atherogenesis, and that arterial plaque can produce CRP, independent of traditional hepatic pathways. In addition to being a strong predictor of future cardiovascular risk amongst patients presenting with acute coronary syndromes, numerous studies have found that baseline levels of CRP are associated with risk of future myocardial infarction, stroke, peripheral vascular disease and cardiovascular death amongst apparently healthy populations. The combination of measurement of a marker of inflammation with lipid testing may improve upon risk stratification based on lipid testing alone, and intensification of programmes for exercise, weight loss, and smoking cessation is recommended for those with elevated CRP levels. Further trials are needed to confirm the potential benefits of statins amongst individuals with elevated CRP levels.